Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...

Association of HIPEC response in ovarian cancer with PI3K/RAS/Notch gene signatures: A whole transcriptomic analysis of U.S. and French HIPEC treated ovarian cancer patients. This is an ASCO Meeting ...

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more precise, tailored therapy plan. In the rapidly evolving landscape of oncology, ...

Researchers have found that amlodipine, a calcium-channel blocker prescribed to tens of millions of people for high blood pressure, can strip a key immune-evasion protein from the surface of cancer ...

HONG KONG, April 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a ...

Patients with advanced HER2-negative gastric cancer respond differently to immunotherapy based on whether they are Asian or ...

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed ...

A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...

A Rutgers Cancer Institute study in Cell Reports Medicine promises help with both those problems. It identifies a protein ...